Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Revised response criteria for malignant lymphoma.

Bruce D Cheson1, Beate Pfistner, Malik E Juweid

  • 1Division of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA. bdc4@georgetown.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|January 24, 2007
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.

Med (New York, N.Y.)·2022
Same author

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.

Blood advances·2021
Same author

Fair Pricing of Innovative Medicines: An EHA Position Paper.

HemaSphere·2020
Same author

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.

Haematologica·2020
Same author

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.

International journal of environmental research and public health·2020
Same author

Here to Stay: Biosimilars in Hematology.

HemaSphere·2020

New lymphoma response criteria incorporate advanced imaging and diagnostics like positron emission tomography (PET) and flow cytometry. These updated guidelines aim to standardize clinical trial interpretation and drug approval for better patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Medical Imaging

Background:

  • Standardized response criteria are crucial for interpreting clinical trials and regulatory approval of new lymphoma therapies.
  • Previous International Working Group criteria (Cheson et al, 1999) required updates due to limitations and advancements in diagnostic techniques.

Purpose of the Study:

  • To present updated international guidelines for assessing response in lymphoma clinical trials.
  • To incorporate novel diagnostic modalities into standardized response definitions.

Main Methods:

  • Convening the International Harmonization Project to reassess existing criteria.
  • Integrating data from [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry.

Related Experiment Videos

Main Results:

  • New guidelines are provided for defining response in Hodgkin's and non-Hodgkin's lymphoma.
  • Incorporation of PET, IHC, and flow cytometry into response assessment.
  • Standardized definitions for clinical trial end points are established.

Conclusions:

  • The updated guidelines are expected to be widely adopted by research groups, industry, and regulatory agencies.
  • Facilitation of new and improved lymphoma therapies through standardized evaluation.
  • Ultimately aiming to enhance treatment outcomes for lymphoma patients.